Article Details
Retrieved on: 2024-05-18 19:10:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In late March, the FDA approved ravulizumab (Ultomiris; Alexion), a terminal compliment C5 inhibitor, as a new treatment for patients with ...
Article found on: www.neurologylive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here